Prolactinoma and body weight: A retrospective study

Creemers, Laura B.; Zelissen, Pierre; Verlaat, J. W. van 't; Koppeschaar, H. P. F.

doi:10.1530/acta.0.1250392

Cited by 55 publications

(31 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study describing the association of Prl and weight in 47 patients with prolactinoma, before treatment, over 50% of patients reported weight gain after the disease (11.8±2.0 kg), with mean weight of 83±2.4 kg and BMI of 27.3±0.6 kg/m 2 [11]. In another study, in which 42 patients with prolactinoma were evaluated and 36 individuals with clinically non-functioning adenomas (NFA) were used as controls, a high prevalence of obesity was also described in prolactinomas [12].…”

Section: Discussionmentioning

confidence: 99%

“…In recent years, some studies have shown an increased prevalence of obesity in patients with prolactinomas [11,12], while others have reported weight loss [12][13][14][15] or weight gain after treatment of hyperprolactinemia [16,17]. However, there are no studies investigating variations in body weight associated with different degrees of hyperprolactinemia or their relation to the cause of hormone hypersecretion.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hyperprolactinemia and body weight: prevalence of obesity and overweight in patients with hyperprolactinemia

Pereira-Lima¹,

Leães²,

Neto³

et al. 2013

Res J Endocrinol Metab

View full text Add to dashboard Cite

Background and objectives: Recent studies have shown an association between prolactin (Prl) levels and body weight, with increased prevalence of obesity in patients with prolactinomas and weight loss associated with hyperprolactinemia. However, data on variations in body weight associated with different degrees of hyperprolactinemia remain scarce. This study aimed to evaluate the prevalence of obesity and overweight in patients with hyperprolactinemia of various causes and correlate Prl levels with body mass index (BMI). Methods: Medical records of patients with hyperprolactinemia were retrospectively reviewed. Patients were classified according to BMI as normal weight (19.0-24.9), overweight (25-29.9), and class I (30-34.9), class II (35-39.9) and class III (> 40) obesity. Disease etiology was divided into microprolactinoma, macroprolactinoma, and other causes for analysis. Results: Of 138 eligible patients, 52.9% had micro or macroprolactinoma and 65.2% were overweight or obese. Mean patient age was 36.2±13.6 years. Obesity was more prevalent in patients with macroprolactinoma (50%), and overweight in patients with other causes of hyperprolactinemia (37.9%), with no statistical difference between groups. Prl levels were higher in macroprolactinomas, with a statistically significant difference (p<0.001) compared to microprolactinomas and other causes of hyperprolactinemia. Prl was also significantly higher in microprolactinomas than in other causes of hyperprolactinemia (p<0.001). Conclusions: Prevalence of obesity was significantly high in hyperprolactinemic patients, regardless of the degree of obesity and the cause of hyperprolactinemia. It is important to monitor BMI in patients with elevated Prl levels to introduce measures aiming to maintain an ideal weight and reduce associated comorbidities.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Hyperprolactinemia and body weight: prevalence of obesity and overweight in patients with hyperprolactinemia

Pereira-Lima¹,

Leães²,

Neto³

et al. 2013

Res J Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…In addition, excessive body weight gain is often detected in hyperprolactinaemic conditions in female rats (Moore et al 1986;Gerardo-Gettens et al 1989) Author for correspondence: Trino Baptista, Apartato 93, Merida, 5101-A, Venezuela (fax 58-74-638304). and in women (Creemers et al 1991;Ferreira et al 1995). The mechanisms by which hyperprolactinaemia stimulates appetite have not been clarified, but they could be related to the impairment in the gonadal production of oestradiol (Baptista et al 1997 c & d;Dorrington & Gore-Langton 1981;Parada et al 1989).…”

mentioning

confidence: 97%

Glucose Tolerance and Serum Insulin Levels in an Animal Model of Obesity Induced by the Antipsychotic Drug, Sulpiride

Baptista

Lacruz

Hernández

1998

Pharmacology & Toxicology

View full text Add to dashboard Cite

Ahsfruct:To assess the role of insulin in the development of obesity induced by antipsychotic drugs, a glucose tolerance test was conducted in 40 female rats during the peak of sulpiride-induced weight gain and in 40 vehicle-treated animals. The glucose area under the curve did not differ between the groups (P=0.24), however, the area under the insulin curve was significantly decreased by sulpiride (55.252.8 versus 115.6t 18.9, P=0.007). The results suggest that insulin resistance and hyperinsulinaemia are not involved in the excessive weight gain observed in this animal model of drug-induced obesity.

show abstract

“…[1][2][3] Subsequent weight loss after treatment with dopamine agonists has also been reported, 3,4 although this has been disputed in one study that showed weight gain after treatment. 5 We therefore undertook a retrospective study of 37 patients with prolactinoma (22 macroprolactinoma and 15 with microprolactinoma, defined by MRI scan of tumour size) and related body weight changes over 24 months to changes in serum and prolactin concentrations.…”

mentioning

confidence: 99%

Body weight and prolactinoma: a retrospective study

2003

View full text Add to dashboard Cite

Prolactinoma and body weight: A retrospective study

Abstract: Body weight and weight history in association with hormone levels were studied retrospectively in 47 patients with prolactinoma; macroprolactinoma was diagnosed in 36, microprolactinoma in 11 patients. At

Cited by 55 publications

References 16 publications

Hyperprolactinemia and body weight: prevalence of obesity and overweight in patients with hyperprolactinemia

Hyperprolactinemia and body weight: prevalence of obesity and overweight in patients with hyperprolactinemia

Glucose Tolerance and Serum Insulin Levels in an Animal Model of Obesity Induced by the Antipsychotic Drug, Sulpiride

Body weight and prolactinoma: a retrospective study

Contact Info

Product

Resources

About